Vivek Subbiah, MD | Authors

Articles

Key Objectives With Selpercatinib Use in RET Fusion-Positive Thyroid Cancer

February 22, 2022

Vivek Subbiah discusses the phase 1/2 LIBRETTO-001 study which sought to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of selpercatinib in patients with advanced solid tumors.